Display options
Cite
Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, et al. Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Front Med (Lausanne). 2021;8:683990doi: 10.3389/fmed.2021.683990.
Hernández-Breijo, B., Plasencia-Rodríguez, C., Navarro-Compán, V., García-Hoz, C., Nieto-Gañán, I., Sobrino, C., Bachiller-Corral, J., Díaz-Almirón, M., Martínez-Feito, A., Jurado, T., Lapuente-Suanzes, P., Bonilla, G., Pijoán-Moratalla, C., Roy, G., Vázquez-Díaz, M., Balsa, A., Villar, L. M., Pascual-Salcedo, D., & Rodríguez-Martín, E. (2021). Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Frontiers in medicine, 8683990. https://doi.org/10.3389/fmed.2021.683990
Hernández-Breijo, Borja, et al. "Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis." Frontiers in medicine vol. 8 (2021): 683990. doi: https://doi.org/10.3389/fmed.2021.683990
Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, García-Hoz C, Nieto-Gañán I, Sobrino C, Bachiller-Corral J, Díaz-Almirón M, Martínez-Feito A, Jurado T, Lapuente-Suanzes P, Bonilla G, Pijoán-Moratalla C, Roy G, Vázquez-Díaz M, Balsa A, Villar LM, Pascual-Salcedo D, Rodríguez-Martín E. Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Front Med (Lausanne). 2021 Jun 17;8:683990. doi: 10.3389/fmed.2021.683990. eCollection 2021. PMID: 34222289; PMCID: PMC8245775.
Copy Download .nbib Format: NLM
Share it on

Front Med (Lausanne). 2021 Jun 17;8:683990. doi: 10.3389/fmed.2021.683990. eCollection 2021.

Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

Frontiers in medicine

Borja Hernández-Breijo, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, Carlota García-Hoz, Israel Nieto-Gañán, Cristina Sobrino, Javier Bachiller-Corral, Mariana Díaz-Almirón, Ana Martínez-Feito, Teresa Jurado, Paloma Lapuente-Suanzes, Gema Bonilla, Cristina Pijoán-Moratalla, Garbiñe Roy, Mónica Vázquez-Díaz, Alejandro Balsa, Luisa M Villar, Dora Pascual-Salcedo, Eulalia Rodríguez-Martín

Affiliations

  1. Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain.
  2. Rheumatology, La Paz University Hospital, Madrid, Spain.
  3. Immunology, Ramón y Cajal Institute for Health Research, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  4. Rheumatology, Ramón y Cajal Institute for Health Research, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  5. Biostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain.
  6. Immunology, La Paz University Hospital, Madrid, Spain.

PMID: 34222289 PMCID: PMC8245775 DOI: 10.3389/fmed.2021.683990

Abstract

Biological therapies, such as TNF inhibitors (TNFi), are increasing remission (REM) rates in rheumatoid arthritis (RA) patients, although these are still limited. The aim of our study was to analyze changes in the profile of peripheral blood mononuclear cells (PBMC) in patients with RA treated with TNFi in relation to the clinical response. This is a prospective and observational study including 78 RA patients starting the first TNFi. PBMC were analyzed by flow cytometry both at baseline and at 6 months. Disease activity at the same time points was assessed by DAS28, establishing DAS28 ≤ 2.6 as the criteria for REM. Logistic regression models were employed to analyze the association between the changes in PBMC and REM. After 6 months of TNFi treatment, 37% patients achieved REM by DAS28. Patients who achieved REM showed a reduction in the percentage of naive B cells, but only when patients had received concomitant methotrexate (MTX) (OR: 0.59; 95% CI: 0.39-0.91). However, no association was found for patients who did not receive concomitant MTX (OR: 0.85; 95% CI: 0.63-1.16). In conclusion, PBMC, mainly the B-cell subsets, are modified in RA patients with TNFi who achieve clinical REM. A significant decrease in naive B-cell percentage is associated with achieving REM after 6 months of TNFi treatment in patients who received concomitant therapy with MTX.

Copyright © 2021 Hernández-Breijo, Plasencia-Rodríguez, Navarro-Compán, García-Hoz, Nieto-Gañán, Sobrino, Bachiller-Corral, Díaz-Almirón, Martínez-Feito, Jurado, Lapuente-Suanzes, Bonilla, Pijoán-Moratalla, Roy, Vázquez-Díaz, Balsa, Villar, Pascual-Salcedo and Rodríguez-Martín.

Keywords: B cells; TNF inhibitors; autoimmunity; remission; rheumatoid arthritis

Conflict of interest statement

CP-R has received research grants/honoraria from AbbVie, Lilly, Novartis, Pfizer, Sanofi, Biogen and UCB. VN-C reports speaker fees and grants from Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UC

References

  1. Rheumatology (Oxford). 2005 May;44 Suppl 2:ii3-ii7 - PubMed
  2. Rheumatology (Oxford). 2020 Oct 1;59(10):3081-3091 - PubMed
  3. Nat Rev Immunol. 2017 Jan;17(1):60-75 - PubMed
  4. Clin Rheumatol. 2018 Jan;37(1):13-23 - PubMed
  5. Front Immunol. 2020 Aug 27;11:1913 - PubMed
  6. JAMA. 2018 Oct 2;320(13):1360-1372 - PubMed
  7. Int J Rheum Dis. 2019 May;22(5):874-879 - PubMed
  8. Reumatol Clin. 2015 Sep-Oct;11(5):279-94 - PubMed
  9. J Immunol. 2008 Jan 15;180(2):688-92 - PubMed
  10. Front Immunol. 2019 Jun 04;10:1265 - PubMed
  11. Arthritis Res Ther. 2018 Oct 12;20(1):229 - PubMed
  12. Front Immunol. 2019 Jan 18;10:3 - PubMed
  13. Arthritis Rheum. 2010 Sep;62(9):2569-81 - PubMed
  14. Int J Mol Sci. 2019 Mar 16;20(6): - PubMed
  15. PLoS One. 2017 Sep 8;12(9):e0182927 - PubMed
  16. Arthritis Rheumatol. 2018 Nov;70(11):1732-1744 - PubMed
  17. Scand J Clin Lab Invest Suppl. 1968;97:31-50 - PubMed
  18. Arthritis Res. 2001;3(1):13-7 - PubMed
  19. Clin Immunol. 2017 Nov;184:63-69 - PubMed
  20. Rheumatology (Oxford). 2016 Mar;55(3):523-34 - PubMed
  21. Immunity. 2008 Jan;28(1):18-28 - PubMed
  22. J Exp Med. 1991 Feb 1;173(2):487-9 - PubMed
  23. Curr Opin Immunol. 2008 Dec;20(6):632-8 - PubMed
  24. N Engl J Med. 2020 Jul 16;383(3):218-228 - PubMed
  25. Arthritis Res Ther. 2014 Apr 15;16(2):R95 - PubMed
  26. Arthritis Rheum. 2007 Oct;56(10):3226-35 - PubMed
  27. Ann Rheum Dis. 2017 Jun;76(6):960-977 - PubMed
  28. Mediators Inflamm. 2017;2017:6894374 - PubMed
  29. Arthritis Rheum. 2005 Sep;52(9):2625-36 - PubMed
  30. Ann N Y Acad Sci. 2007 Jun;1108:312-22 - PubMed
  31. Clin Rev Allergy Immunol. 2012 Dec;43(3):281-91 - PubMed
  32. Rheumatology (Oxford). 2018 Jan 1;57(1):164-174 - PubMed
  33. Clin Rheumatol. 2015 Apr;34(4):629-34 - PubMed
  34. Ther Adv Musculoskelet Dis. 2010 Oct;2(5):247-56 - PubMed
  35. Arthritis Res Ther. 2009;11(5):128 - PubMed
  36. Nat Rev Rheumatol. 2016 Jan;12(1):37-48 - PubMed
  37. Nat Rev Rheumatol. 2019 May;15(5):303-315 - PubMed
  38. Rheumatology (Oxford). 2004 Oct;43(10):1252-5 - PubMed
  39. N Engl J Med. 2020 Jul 16;383(3):278-279 - PubMed

Publication Types